Introduction: The Warfarin Self-Management Anti-coagulation Research Trial (Warfarin SMART) was designed to determine whether patients self-managing warfarin
(PSM) using the CoaguChek device and a dosing algorithm developed for the trial, could
keep INR in target range at least as often as patients managed by usual care (UC)
by the family doctor or hospital clinic. Most previous trials and meta-analyses about
patient self-management unfairly favour the device and self management or contain
other biases in the design. The Warfarin SMART study was adequately powered to rule
out PSM being inferior to UC by up to a 6% higher rate of out-of-range INRs in an
unbiased design.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Heart, Lung and CirculationAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
Article info
Footnotes
☆Self-Management Anticoagulation Research Trial.
Identification
Copyright
© 2011 Published by Elsevier Inc.
